Engineering Vaccines to Reprogram Immunity against Head and Neck Cancer

Dendritic Cells but Not Macrophages Sense Tumor Mitochondrial DNA for Cross-priming through Signal Regulatory Protein α Signaling

(2017) Meng Michelle Xu et al.   IMMUNITY

An immunogenic personal neoantigen vaccine for patients with melanoma

(2017) Patrick A. Ott et al.   NATURE

Antigen-specific immunotherapies in rheumatic diseases

(2017) Judit Pozsgay et al.   Nature Reviews Rheumatology

Controversies in Postoperative Irradiation of Oropharyngeal Cancer After Transoral Surgery

(2017) Sue S. Yom et al.   Surgical Oncology Clinics of North America

Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells

(2017) Paul E. Clavijo et al.   Oncotarget

Increased PD-1 + and TIM-3 + TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients

(2017) Hyun-Bae Jie et al.   Cancer Immunology Research

MVX-ONCO-1 phase 1 final results of the first personalized cell-based immunotherapy using cell encapsulation technology

(2016) N. Mach et al.   ANNALS OF ONCOLOGY

A phase 1/2a study to test the safety and immunogenicity of a p16INK4apeptide vaccine in patients with advanced human papillomavirus-associated cancers

(2016) Miriam Reuschenbach et al.   CANCER

Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting

(2016) Julie E. Bauman et al.   CANCER

Therapeutic Efficacy of Cancer Stem Cell Vaccines in the Adjuvant Setting

(2016) Y. Hu et al.   CANCER RESEARCH

CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell-Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1

(2016) Y. Lee et al.   CLINICAL CANCER RESEARCH

Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma

(2016) Nghia Nguyen et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction

(2016) Nicole E. Scharping et al.   IMMUNITY

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

(2016) Tanguy Y Seiwert et al.   LANCET ONCOLOGY

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

EGFR-targeted mAb therapy modulates autophagy in head and neck squamous cell carcinoma through NLRX1–TUFM protein complex

(2016) Y Lei et al.   ONCOGENE

Telltale tumor infiltrating lymphocytes (TIL) in oral, head & neck cancer

(2016) Yu Lei et al.   ORAL ONCOLOGY

Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer

(2016) Ruth J. Davis et al.   ORAL ONCOLOGY

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade

(2016) E. Moore et al.   Cancer Immunology Research

Immunotherapy for head and neck cancer: latest developments and clinical potential

(2016) Joshua M. Bauml et al.   Therapeutic Advances in Medical Oncology

Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer

(2016) Gulidanna Shayan et al.   OncoImmunology

Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFN  That Induce PD-L1 Expression in Head and Neck Cancer

(2015) F. Concha-Benavente et al.   CANCER RESEARCH

Comprehensive genomic characterization of head and neck squamous cell carcinomas

(2015)   NATURE

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

(2015) E. M. Van Allen et al.   SCIENCE

STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade

(2015) Juan Fu et al.   Science Translational Medicine

A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN)

(2014) Dan P. Zandberg et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

PD-1/SHP-2 Inhibits Tc1/Th1 Phenotypic Responses and the Activation of T Cells in the Tumor Microenvironment

(2014) J. Li et al.   CANCER RESEARCH

Tadalafil Reduces Myeloid-Derived Suppressor Cells and Regulatory T Cells and Promotes Tumor Immunity in Patients with Head and Neck Squamous Cell Carcinoma

(2014) D. T. Weed et al.   CLINICAL CANCER RESEARCH

Phase I Dendritic Cell p53 Peptide Vaccine for Head and Neck Cancer

(2014) P. J. Schuler et al.   CLINICAL CANCER RESEARCH

Phase II Clinical Trial of Multiple Peptide Vaccination for Advanced Head and Neck Cancer Patients Revealed Induction of Immune Responses and Improved OS

(2014) Y. Yoshitake et al.   CLINICAL CANCER RESEARCH

STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors

(2014) Seng-Ryong Woo et al.   IMMUNITY

STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors

(2014) Liufu Deng et al.   IMMUNITY

Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice

(2014) Liufu Deng et al.   JOURNAL OF CLINICAL INVESTIGATION

Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma

(2013) S. Lyford-Pike et al.   CANCER RESEARCH

SHP2 Is Overexpressed and Inhibits pSTAT1-Mediated APM Component Expression, T-cell Attracting Chemokine Secretion, and CTL Recognition in Head and Neck Cancer Cells

(2013) M. S. Leibowitz et al.   CLINICAL CANCER RESEARCH

Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia

(2013) J. Baginska et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Mitochondrial Proteins NLRX1 and TUFM Form a Complex that Regulates Type I Interferon and Autophagy

(2012) Yu Lei et al.   IMMUNITY

Tumor-associated macrophages and the profile of inflammatory cytokines in oral squamous cell carcinoma

(2012) Nadia Lago Costa et al.   ORAL ONCOLOGY

Lm-LLO-Based Immunotherapies and HPV-Associated Disease

(2012) Anu Wallecha et al.   Journal of Oncology

HPV L1 Capsid Protein Detection and Progression of Anal Squamous Neoplasia

(2011) Jonathan Hernandez et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

The Present and Future of Peptide Vaccines for Cancer

(2011) Craig L. Slingluff   CANCER JOURNAL

Cetuximab Therapy for Head and Neck Squamous Cell Carcinoma

(2011) Travis D. Reeves et al.   OTOLARYNGOLOGY-HEAD AND NECK SURGERY

The Mutational Landscape of Head and Neck Squamous Cell Carcinoma

(2011) N. Stransky et al.   SCIENCE

The CD8+dendritic cell subset

(2010) Ken Shortman et al.   IMMUNOLOGICAL REVIEWS

Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia

(2009) Gemma G. Kenter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Innate Immune Sensing of Modified Vaccinia Virus Ankara (MVA) Is Mediated by TLR2-TLR6, MDA-5 and the NALP3 Inflammasome

(2009) Julie Delaloye et al.   PLoS Pathogens

Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity

(2008) G. G. Kenter et al.   CLINICAL CANCER RESEARCH